Kura Oncology granted stock options to new employees as inducement under its 2023 Inducement Option Plan.
Quiver AI Summary
Kura Oncology, Inc. announced that it has granted inducement awards consisting of nonstatutory stock options to six new employees, allowing them to purchase 153,750 shares of the company's common stock at an exercise price of $8.34 per share. This grant, made by the Compensation Committee on April 1, 2026, is aimed at attracting talent in line with Nasdaq Listing Rule 5635(c)(4). The stock options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the next 36 months, contingent on the employees' continued service. Kura specializes in precision medicines for cancer treatment and has developed KOMZIFTI™, an FDA-approved oral menin inhibitor for specific leukemia types.
Potential Positives
- Granting stock options to six new employees can enhance talent acquisition and retention, indicating the company's commitment to building a skilled workforce.
- The inducement awards align with Nasdaq Listing Rule requirements, demonstrating compliance with regulatory standards, which can enhance investor confidence.
- The stock options are granted at the current market price, which may incentivize employees to drive the company’s performance and stock value upward.
- Kura’s focus on precision medicines and established products like KOMZIFTI™ highlights its ongoing commitment to innovation in cancer treatment, potentially attracting further investment and strategic partnerships.
Potential Negatives
- The issuance of stock options to six new employees could indicate difficulties in attracting talent without significant inducements, suggesting potential challenges in the company's employment attractiveness.
- Granting nonstatutory stock options may dilute existing shareholder equity, raising concerns among investors regarding the financial impact of such awards on the company's stock value.
- The need to offer inducement awards under the 2023 Inducement Option Plan may reflect underlying organizational issues, such as high turnover rates or difficulties in retaining key personnel, which could hinder operational stability.
FAQ
What stock options did Kura Oncology grant in April 2026?
Kura Oncology granted inducement awards of nonstatutory stock options to purchase 153,750 shares to six new employees.
What is the exercise price of the stock options?
The exercise price of each stock option is $8.34 per share, equal to the closing price on April 1, 2026.
How will the stock options vest for new employees?
The stock options will vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting monthly thereafter.
What is the purpose of Kura's 2023 Inducement Option Plan?
The 2023 Inducement Option Plan aims to incentivize and attract new employees by offering stock options as part of their compensation.
What is Kura Oncology focused on in their drug development?
Kura Oncology focuses on precision medicines targeting cancer signaling pathways for hematologic malignancies and solid tumors.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$KURA Insider Trading Activity
$KURA insiders have traded $KURA stock on the open market 23 times in the past 6 months. Of those trades, 0 have been purchases and 23 have been sales.
Here’s a breakdown of recent trading of $KURA stock by insiders over the last 6 months:
- FRANCIS BURROWS (Chief Scientific Officer) has made 0 purchases and 2 sales selling 25,037 shares for an estimated $243,023.
- MOLLIE LEONI (Chief Medical Officer) has made 0 purchases and 5 sales selling 23,665 shares for an estimated $242,282.
- TERESA BROPHY BAIR (Chief Legal Officer) has made 0 purchases and 4 sales selling 20,012 shares for an estimated $193,228.
- BRIAN T. POWL (Chief Commercial Officer) has made 0 purchases and 3 sales selling 15,301 shares for an estimated $153,595.
- THOMAS JAMES DOYLE (SVP, Finance & Accounting) has made 0 purchases and 6 sales selling 11,681 shares for an estimated $111,158.
- FAHEEM HASNAIN sold 10,000 shares for an estimated $109,764
- KATHLEEN FORD (Chief Operating Officer) has made 0 purchases and 2 sales selling 8,715 shares for an estimated $92,482.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$KURA Hedge Fund Activity
We have seen 129 institutional investors add shares of $KURA stock to their portfolio, and 80 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- STATE STREET CORP added 1,587,959 shares (+47.5%) to their portfolio in Q4 2025, for an estimated $16,498,894
- ALGERT GLOBAL LLC removed 1,011,945 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $10,514,108
- RENAISSANCE TECHNOLOGIES LLC added 965,256 shares (+111.6%) to their portfolio in Q4 2025, for an estimated $10,029,009
- ECOR1 CAPITAL, LLC removed 872,500 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $9,065,275
- AQR CAPITAL MANAGEMENT LLC added 820,020 shares (+36.6%) to their portfolio in Q4 2025, for an estimated $8,520,007
- NAN FUNG TRINITY (HK) LTD added 734,000 shares (+317.9%) to their portfolio in Q4 2025, for an estimated $7,626,260
- UBS GROUP AG added 574,455 shares (+118.3%) to their portfolio in Q4 2025, for an estimated $5,968,587
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$KURA Analyst Ratings
Wall Street analysts have issued reports on $KURA in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 11/24/2025
- Wedbush issued a "Outperform" rating on 11/14/2025
- UBS issued a "Buy" rating on 11/14/2025
- JMP Securities issued a "Market Outperform" rating on 10/20/2025
To track analyst ratings and price targets for $KURA, check out Quiver Quantitative's $KURA forecast page.
$KURA Price Targets
Multiple analysts have issued price targets for $KURA recently. We have seen 7 analysts offer price targets for $KURA in the last 6 months, with a median target of $25.0.
Here are some recent targets:
- Mara Goldstein from Mizuho set a target price of $25.0 on 03/24/2026
- David Dai from UBS set a target price of $15.0 on 03/13/2026
- Robert Driscoll from Wedbush set a target price of $36.0 on 03/06/2026
- Joseph Pantginis from HC Wainwright & Co. set a target price of $40.0 on 01/13/2026
- An analyst from Leerink Partners set a target price of $20.0 on 01/13/2026
- Etzer Darout from Barclays set a target price of $28.0 on 11/24/2025
- Reni J. Benjamin from JMP Securities set a target price of $24.0 on 10/20/2025
Full Release
SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on April 1, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 153,750 shares of common stock to six (6) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price equal to $8.34 per share, the closing price of the Company’s common stock on April 1, 2026, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company’s 2023 Inducement Option Plan, as amended, and the terms and conditions of an applicable stock option agreement covering the grant.
About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™, the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory
NPM1
-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at
https://kuraoncology.com/
and follow us on
X
and
LinkedIn
.
Kura Contact
Investors and Media:
Greg Mann
858-987-4046
[email protected]
